TD Asset Management Inc. lessened its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 5.5% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 66,491 shares of the medical equipment provider’s stock after selling 3,875 shares during the quarter. TD Asset Management Inc.’s holdings in Zimmer Biomet were worth $7,785,000 as of its most recent SEC filing.
A number of other large investors have also recently added to or reduced their stakes in ZBH. Bronfman E.L. Rothschild L.P. grew its stake in Zimmer Biomet by 25.3% during the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 827 shares of the medical equipment provider’s stock worth $106,000 after buying an additional 167 shares during the last quarter. BB&T Investment Services Inc. purchased a new position in shares of Zimmer Biomet in the 2nd quarter valued at approximately $144,000. Sandy Spring Bank grew its stake in shares of Zimmer Biomet by 5.4% in the 2nd quarter. Sandy Spring Bank now owns 1,288 shares of the medical equipment provider’s stock valued at $166,000 after purchasing an additional 66 shares during the last quarter. Penserra Capital Management LLC grew its stake in shares of Zimmer Biomet by 13.0% in the 2nd quarter. Penserra Capital Management LLC now owns 1,456 shares of the medical equipment provider’s stock valued at $186,000 after purchasing an additional 168 shares during the last quarter. Finally, Stonebridge Capital Advisors LLC purchased a new position in shares of Zimmer Biomet in the 2nd quarter valued at approximately $202,000. Hedge funds and other institutional investors own 86.24% of the company’s stock.
Zimmer Biomet Holdings, Inc. (NYSE ZBH) traded up $0.25 on Tuesday, hitting $114.82. The stock had a trading volume of 1,382,900 shares, compared to its average volume of 1,358,894. The company has a quick ratio of 0.78, a current ratio of 1.47 and a debt-to-equity ratio of 0.88. The firm has a market cap of $23,460.00, a PE ratio of 14.20, a P/E/G ratio of 1.78 and a beta of 1.15. Zimmer Biomet Holdings, Inc. has a 1-year low of $100.16 and a 1-year high of $133.49.
Several brokerages have weighed in on ZBH. Morgan Stanley lowered their target price on Zimmer Biomet from $146.00 to $136.00 and set an “overweight” rating on the stock in a research note on Thursday, November 2nd. BMO Capital Markets lowered their target price on Zimmer Biomet from $140.00 to $135.00 and set an “outperform” rating on the stock in a research note on Thursday, November 2nd. Piper Jaffray Companies downgraded Zimmer Biomet from an “overweight” rating to a “neutral” rating in a research note on Thursday, November 2nd. SunTrust Banks set a $136.00 target price on Zimmer Biomet and gave the company a “buy” rating in a research note on Wednesday, November 1st. Finally, Zacks Investment Research downgraded Zimmer Biomet from a “hold” rating to a “strong sell” rating in a research note on Tuesday, August 8th. Four research analysts have rated the stock with a sell rating, seven have assigned a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $133.71.
WARNING: This article was originally reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this article on another publication, it was illegally copied and republished in violation of US & international copyright & trademark law. The original version of this article can be viewed at https://sportsperspectives.com/2017/12/05/td-asset-management-inc-reduces-position-in-zimmer-biomet-holdings-inc-zbh.html.
Zimmer Biomet Company Profile
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.